Chemical Reprogramming of Somatic Cells in Neural Direction: Myth or Reality?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

In in vitro experiments on cultures of human multipotent stem cells from the human bone

arrow and dental pulp, we studied direct reprogramming towards neuro-glial lineage cells using a cocktail of small molecules. Reprogramming by the previously published protocol (with a cocktail containing β-mercaptoethanol, LIF, VPA, CHIR99021, and RepSox) and by the optimized protocol (VPA, RG108, А83-01, dorsomorphin, thiazovivin, CHIR99021, forskolin, and Isx9) allows obtaining cells with immunophenotypic and genetic signs of neural stem cells. However, neither the former, nor the optimized protocols allowed preparing neural progenitors capable of adequate terminal differentiation from both bone marrow-derived mesenchymal stem cells and nestin-positive neural crest-derived mesenchymal stem cells. Real-time PCR demonstrated the expression of some neurogenesis markers, but neural stem cell-specific expression pattern was not observed. The findings lead us to a conclusion that reprogramming with small molecules without additional factors modifying gene expression does not allow reproducible production of human neural stem cell-like progenitors that can be used as the source of neural tissue for the regenerative therapy.

About the authors

E. M. Samoilova

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: samoyket@gmail.com
Russian Federation, Moscow

V. A. Revkova

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow

O. I. Brovkina

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow

V. A. Kalsin

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow

P. A. Melnikov

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia; Department of Fundamental and Applied Neurobiology, V. P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: samoyket@gmail.com
Russian Federation, Moscow; Moscow

M. A. Konoplyannikov

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia; Institute of Regenerative Medicine, I. M. Sechenov First Moscow State Medical University (Sechenov University)

Email: samoyket@gmail.com
Russian Federation, Moscow; Moscow

K. R. Galimov

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow

A. G. Nikitin

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow

A. V. Troitskiy

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow

V. P. Baklaushev

Federal Research Clinical Center of Specialized Medical Care, Federal Medical-Biological Agency of Russia

Email: samoyket@gmail.com
Russian Federation, Moscow


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies